Abstract 1845P
Background
ICIs are used in many solid tumors and is better tolerated than chemotherapy. However, irAEs are a concerning toxicity. Studies suggest that BMI may influence irAEs rates. We conducted a population-level study to evaluate BMI on irAEs and acute care use in patients receiving ICIs.
Methods
We used administrative data deterministically linked across databases to identify a cohort of solid tumors patients initiating ICI therapy in Ontario, Canada from June 2012-October 2018. We collected information on socio-demographics including BMI at start of ICI, clinical covariates and outcomes including acute care use and irAEs within 120 days of the last ICI dose. Multivariable Fine Gray competing risk analyses evaluated the impact of BMI on irAEs and acute care use, treating death as a competing event.
Results
Among 4683 patients, median age was 67, 57% were male; 46% had lung cancer, 35% melanoma, 9% renal; Median BMI was 26.1 (3% low, 29% normal, 27% overweight, 19% obese). Overall, 57% had an acute care episode while 7% of patients had an irAE requiring hospitalization. Increased BMI was associated with increased rate of irAEs (aHR=1.03 per 1 unit increase, 95% CI [1.01-1.04] p<0.001). Compared to patients with normal BMI, obese (aHR=1.60 [1.21-2.11] p<0.001) patients had a higher rate of irAEs. Subgroup analysis by gender found that females with increasing BMI (aHR=1.03 per unit increase [1.00-1.06] p=0.02) and obesity (aHR=2.01 [1.30-3.09] p=0.002) had higher rates of irAEs. Disease site analyses found that in patients with melanoma, obesity when compared to normal BMI (aHR=1.67 [1.10-2.53] p=0.02) was associated with increase in irAEs. In particular, in females with melanoma, obesity compared to normal BMI was strongly associated with increased irAEs (aHR=2.60 [1.36-4.96] p<0.004). BMI was not associated with overall general acute care use as a continuous or categorical variable (p>0.05).
Conclusions
Increasing BMI and obesity is associated with increasing risk for irAEs but not acute care use. The association was strongest for female patients and those with melanoma. Further research is needed to understand the mechanism of action behind this association.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
L. Eng.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1853P - Risk model for overall survival (OS) based on composite patient-reported outcomes (PROs) in aNSCLC patients treated with first-line (1L) cemiplimab-based therapy
Presenter: David Gandara
Session: Poster session 12
1854P - Assessing mortality rates within 30 days following the last dose of immunotherapy: A multi-center retrospective study
Presenter: Kadriye Baskurt
Session: Poster session 12
1855P - Analyzing the utility of the cancer therapy satisfaction questionnaire (CTSQ)
Presenter: Carolina Navas
Session: Poster session 12
1856P - Prediction of clinically significant bleeding in anticoagulated patients for cancer-associated venous thromboembolism: Validation of B-CAT score in a cohort from the TESEO study
Presenter: Javier López Robles
Session: Poster session 12
1857P - Machine learning models (MLM) predict venous thromboembolism events (VTE) in Asian oncological inpatients better than the Khorana Score (KS)
Presenter: Jerold Loh
Session: Poster session 12
1858P - Efficacy and safety of thromboprophylaxis in oncology patients with Khorana score<2: Combined results from GMaT and ACT4CAT studies
Presenter: Nikolaos Tsoukalas
Session: Poster session 12
1860P - The impact of sodium-glucose cotransporter-2 inhibitors on thrombosis and cardiovascular disease in patients with polycythemia vera or essential thrombocytopenia
Presenter: Yuanping Hsia
Session: Poster session 12
1861P - Poly (ADP-Ribose) polymerase inhibitors (PARPI): Associated thrombosis in patients with ovarian cancer
Presenter: Manuel Sanchez Canovas
Session: Poster session 12
1862P - A single-arm, phase II trial of hetrombopag for the treatment of concurrent chemoradiotherapy-induced thrombocytopenia in patients with advanced solid tumors
Presenter: Weiwen Zhou
Session: Poster session 12
1863P - Circulating biomarkers for risk stratification of cancer patients with chemotherapy associated febrile neutropenia
Presenter: Sofía Wikström Fernandez
Session: Poster session 12